stockrow
Friday 6 November 2026
Export NEO’s income statement to Excel — free account
NeoGenomics, Inc.
NEO Healthcare Diagnostics & Research
NeoGenomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $727.3 million, up 10.1% from fiscal 2024.
- Revenue
- +11.4%
- EPS
- +72.1%
- Free cash flow
- −3,724.2%
- Total debt
- +10.9%
Quarter to September 2026, against a year earlier
16.62
0.13
+0.79%
Follow NEO
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.07 | 1.28 | 2.47 | 3.00 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
1,121.72 | (117.78) | 94.76 | (265.71) | |
P/B ratio |
1.80 | 1.16 | 2.41 | 2.95 | |
Price to Tangible BV |
58.64 | 37.05 | 0.00 | 181.39 | |
EV/Sales |
2.60 | 1.82 | 3.03 | 3.56 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 160.04 | |
EV/Operating CF |
361.35 | 60.47 | 105.45 | 654.57 | |
EV/FCF |
(95.87) | (448.59) | (439.62) | (105.65) | |
Quick Ratio |
3.61 | 3.71 | 3.03 | 3.04 | |
Current Ratio |
4.26 | 4.42 | 3.60 | 3.53 | |
Net Debt/EBITDA |
54.18 | (107.27) | 32.27 | 27.36 | |
Debt/Assets |
25.14% | 25.42% | 27.97% | 27.51% | |
Debt/Equity |
0.41 | 0.41 | 0.48 | 0.47 | |
Asset Turnover |
0.49 | 0.51 | 0.56 | 0.57 | |
Operating CF/Net income |
(0.14) | 0.48 | 8.92 | 1.18 | |
Capex/Depreciation |
(0.35) | (0.30) | (0.48) | (0.71) | |
Interest Coverage |
(22.39) | (30.50) | (12.51) | (6.27) | |
Research and Development Expense of Revenue |
4.83% | 5.11% | 5.34% | 4.71% | |
Selling, General and Administrative Expense of Revenue |
45.72% | 47.98% | 45.07% | 45.24% | |
Intangible Assets out of Total Assets |
0.60 | 0.60 | 0.59 | 0.57 | |
Share Based Compensation of Revenue |
4.23% | 5.16% | 4.07% | 4.22% | |
Graham Net Nets |
(0.10) | (0.15) | (0.10) | (0.07) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.14%) | (10.38%) | (2.74%) | (1.35%) | |
Free Cash Flow Yield |
(1.31%) | (0.32%) | (0.28%) | (1.12%) | |
Revenue per Share |
1.48 | 1.45 | 1.56 | 1.63 | |
Operating CF per Share |
0.01 | (0.06) | 0.15 | (0.07) | |
Capex per Share |
(0.05) | (0.04) | (0.06) | (0.09) | |
Free Cash Flow per Share |
(0.03) | (0.10) | 0.09 | (0.16) | |
Cash per Share |
1.25 | 1.13 | 1.12 | 1.08 | |
Shareholders Equity per Share |
6.53 | 6.42 | 6.06 | 6.23 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
6.53 | 6.42 | 6.06 | 6.23 | |
Free Cash Flow |
(4.46) | (13.14) | 11.74 | (20.66) | |
Working Capital |
287.99 | 289.09 | 275.60 | 293.91 | |
Capital Expenditures |
(5.80) | (5.00) | (8.22) | (11.77) | |
Net Current Asset Value |
(146.98) | (144.09) | (185.03) | (166.20) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.03 | 0.04 | 0.06 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
154.89 | 159.32 | 164.27 | 184.35 | |
Average Payables |
22.35 | 21.05 | 24.22 | 27.77 | |
Average Inventory |
27.66 | 29.80 | 30.65 | 26.98 | |
Average Assets |
1,498.93 | 1,473.98 | 1,373.10 | 1,375.85 | |
Average Common Equity |
869.45 | 858.51 | 819.89 | 819.46 |
Columns are period end dates · fundamentals updated 2 Nov 2026